Clinical practice guidelines recognize oral fluid screening as a valid alternative to urine tests for assessing drug use. In this test-specific episode of the "Answers From the Lab" podcast, Paul Jannetto, Ph.D., explains the advantages provided by Mayo Clinic Laboratories' oral fluid screening.

"Most urine collections are not witnessed. Therefore, urine is easy to adulterate or even substitute," Dr. Jannetto says. "Direct observation of oral fluid screening is simple. Drugs also tend to be detected sooner in oral fluid versus urine."

Mayo Clinic Laboratories' cost-effective immunoassay panel includes tests for opioids, benzodiazepines, barbiturates, marijuana, stimulants such as methamphetamine, and PCP (phencyclidine).

"Oral toxicology tests can assist the clinician in identifying when patients are not taking prescribed medications and can also provide information about other drug use that wasn't reported to the physician," Dr. Jannetto says. "Toxicology drug tests are a tool to support recovery and provide motivation for compliance."

Listen to learn more about Mayo Clinic Laboratories' oral fluid drugs of abuse screen.

Note: Podcasts will not play back on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.

Testing

CSMOF   | Controlled Substance Monitoring Panel, 11 Drug Classes, Screen Only, Immunoassay, Oral Fluid

The latest

Unique Test Screens for Recently Identified Peripheral Neuropathy: Matthew Schultz, Ph.D., and Amy White, M.S., CGC

September 24, 2024

Matthew J. Schultz, Ph.D., and Amy L. White, M.S., CGC, explain how Mayo Clinic Laboratories' unique urine assay (Mayo ID: SORD) screens for peripheral neuropathy arising from SORD gene variants. Although recently identified, SORD-related peripheral neuropathy is fairly common.

Panel Detects Demyelinating Neuropathy Biomarkers: John Mills, Ph.D., and Divyanshu Dubey, M.B.B.S.

September 17, 2024

John Mills, Ph.D., and Divyanshu Dubey, M.B.B.S., explain how Mayo Clinic Laboratories' new test panel can distinguish among various potential causes of demyelinating neuropathies. Test results are important for managing these devastating autoimmune conditions.

Genetic Tests Identify Risk of Fluoropyrimidine-Induced Toxicity: Ann Moyer, M.D., Ph.D.

September 10, 2024

Ann Moyer, M.D., Ph.D., explains how Mayo Clinic Laboratories' unique genetic tests identify patients at high risk of severe reactions to fluoropyrimidines — a type of chemotherapy drug. Test results can guide clinical decision-making for safer cancer treatment.

View MoreView Less